Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer reports positive data from new Lyrica trial

Pfizer reports positive data from new Lyrica trial

22nd June 2011

Pfizer has published positive new clinical trial data from a phase III study assessing the drug Lyrica as a treatment for central neuropathic pain following spinal cord injury.

The A0081107 trial assessed a flexible dose of the drug compared to placebo among a total of 220 back injury patients based in ten different countries.

According to results from the programme, Pfizer's drug was able to meet its primary endpoint by demonstrating an improvement in pain scores for the duration of the study.

Dr Steven Romano, senior vice-president and head of the medicines development group at Pfizer's global primary care business unit, said: "We are pleased with the top-line results of this study and look forward to more fully understanding the benefit that Lyrica may bring to these patients."

The drug is already approved in 110 countries worldwide as a therapy for conditions such as diabetic nerve pain, fibromyalgia and pain after shingles.

Earlier this month, the company commenced an innovative new "virtual" clinical trial that will allow patients to take part remotely using mobile and online technology.ADNFCR-8000103-ID-800590096-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.